BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rinzimetostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rinzimetostat\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05413421-10910@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rinzimetostat: Phase 1 readout est. (NCT05413421)
DESCRIPTION:Rinzimetostat\, phase 1\, Prostate Cancer.\nStudy: Study of ORI
 C-944 in Patients With Metastatic Prostate Cancer\nEstimated primary compl
 etion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rin
 zimetostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05413421
URL:https://assetmemo.bio/drug/rinzimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07723248-10910@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rinzimetostat: Phase 3 readout est. (NCT07723248)
DESCRIPTION:Rinzimetostat\, phase 3\, Prostate Cancer.\nStudy: A Study to L
 earn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients W
 ith mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-
 1)\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rinzimetostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07723248
URL:https://assetmemo.bio/drug/rinzimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
